Woolcock Institute of Medical Research, University of Sydney, Glebe Point Road, Glebe, 2037 NSW, Australia; Department of Respiratory & Sleep Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia.
Respir Physiol Neurobiol. 2013 Sep 15;188(3):257-66. doi: 10.1016/j.resp.2013.05.007. Epub 2013 May 16.
Understanding the inter-relationship between pharmacological agents, ventilatory control, upper airway physiology and their consequent effects on sleep-disordered breathing may provide new directions for targeted drug therapy. Where available, this review focuses on human studies that contain both drug effects on sleep-disordered breathing and measures of ventilatory control or upper airway physiology. Many of the existing studies are limited in sample size or comprehensive methodology. At times, the presence of paradoxical findings highlights the complexity of drug therapy for OSA. The existing studies also highlight the importance of considering inter-individual pharmacokinetics and underlying causes of sleep apnea in interpreting drug effects on sleep-disordered breathing. Practical ways to assess an individual's ventilatory control and how it interacts with upper airway physiology is required for future targeted pharmacotherapy in sleep apnea.
了解药理作用、通气控制、上呼吸道生理学及其对睡眠呼吸障碍的影响之间的相互关系,可能为靶向药物治疗提供新的方向。在有条件的情况下,本综述侧重于包含药物对睡眠呼吸障碍的影响以及通气控制或上呼吸道生理学测量的人体研究。许多现有研究在样本量或综合方法学方面存在局限性。有时,矛盾发现的存在凸显了药物治疗 OSA 的复杂性。现有的研究还强调了在解释药物对睡眠呼吸障碍的影响时,考虑个体药代动力学和睡眠呼吸暂停的潜在原因的重要性。需要评估个体通气控制及其与上呼吸道生理学相互作用的实用方法,以便在未来对睡眠呼吸暂停进行靶向药物治疗。